Status Purchase has not taken place
Estimated value without VAT 1 131 600 MDL
Period of clarifications: 13 Sep 2021, 13:53 - 23 Sep 2021, 10:00
Submission of proposals: 23 Sep 2021, 10:00 - 29 Sep 2021, 10:00
Auction start date: will not be used

Supplier technical support:

(+373) 79999801


This procedure is carried out without auction. Your offer is final and must contain the entire list of required documents.

Vaccin antirabic 2.5UI/doză (1.0ml) + Immunoglobulinum antirabicum nu mai puțin de 150UI/ml
Information about customer
Fiscal code/IDNO
Address
MD-2009, MOLDOVA, mun.Chişinău, locality, MD-2009, Republica Moldova, Chişinău str. Cosmescu 3
Web site
---
The contact person
Full name
Macari Doina
Contact phone
+37322222490
Purchase data
Date created
Date modified
29 Sep 2021, 10:00
Estimated value (without VAT)
1 131 600 MDL
Achizitii.md ID
21044182
Type of procedure
Open tender
Award criteria
The lowest price
Delivery address
MD-2009, MOLDOVA, mun.Chişinău, mun.Chişinău, Agenția Națională pentru Sănătate Publică
Contract period
1 Jan 2022 02:00 - 31 Dec 2022 02:00
List of positions
1)
Title
Vaccin antirabic 2.5UI/doză (1.0ml) CPV: 33600000-6 - Pharmaceutical products
Quantity: 12000.0
Unit of measurement: Bucata
2)
Title
Immunoglobulinum antirabicum nu mai puțin de 150UI/ml CPV: 33600000-6 - Pharmaceutical products
Quantity: 50.0
Unit of measurement: Bucata
Documents of the procurement procedure
Documentația standard.semnat
Bidding Documents
Documentația Standard
13.09.21 13:53
DUAE model
Bidding Documents
DUAE model
13.09.21 13:53
declaratie_ro
Bidding Documents
Declarație OE
13.09.21 13:53
Contract model
Bidding Documents
Contract model
13.09.21 13:53
Forma_4_1
Technical Specifications
Specificații tehnice
13.09.21 13:53
Forma_4_2
Technical Specifications
Specificații de preț
13.09.21 13:53
anunt_de_participare.semnat
Bidding Documents
Anunț de participare
13.09.21 13:53
The history of the auction
View auction
Litigation
File an appeal
Unfortunately, questions can be asked only during the "Active" period.
Clarifications